← Back to Search

Patient/Proxy-SSPedi Administered First for Pediatric Cancer

N/A

Waitlist Available

Led By Lillian Sung, MD, PhD

Research Sponsored by The Hospital for Sick Children

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up immediately after the intervention

Awards & highlights

Study Summary

This trial will compare how well different versions of the SSPedi tool work in measuring symptoms in children receiving cancer treatments.

Eligible Conditions

Pediatric Cancer
Quality of Life
Symptom Screening

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ immediately after the intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~immediately after the intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after the intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Symptom Screening in Pediatrics Tool (SSPedi) total score

Trial Design

2Treatment groups

Experimental Treatment

Group I: Patient/Proxy-SSPedi Administered FirstExperimental Treatment2 Interventions

Parent/child dyads will complete self-report SSPedi/mini-SSPedi and proxy-SSPedi as the first "period" and then co-SSPedi as a second "period".

Group II: Co-SSPedi Administered FirstExperimental Treatment2 Interventions

Parent/child dyads will complete co-SSPedi as the first "period" and then self-report SSPedi/mini-SSPedi and proxy-SSPedi as a second "period".

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

The Hospital for Sick ChildrenLead Sponsor

686 Previous Clinical Trials

6,944,373 Total Patients Enrolled

Lillian Sung, MD, PhDPrincipal InvestigatorThe Hospital for Sick Children

4 Previous Clinical Trials

785 Total Patients Enrolled

Media Library

Patient/Proxy-SSPedi Administered First Clinical Trial Eligibility Overview. Trial Name: NCT05012917 — N/A

Pediatric Cancer Research Study Groups: Patient/Proxy-SSPedi Administered First, Co-SSPedi Administered First

Pediatric Cancer Clinical Trial 2023: Patient/Proxy-SSPedi Administered First Highlights & Side Effects. Trial Name: NCT05012917 — N/A

Patient/Proxy-SSPedi Administered First 2023 Treatment Timeline for Medical Study. Trial Name: NCT05012917 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots open for participants in this research?

"As of 2/11/2022, this clinical trial is actively recruiting participants. The initial posting date was 8/19/2021 and the listing has been kept up to date since then."

Answered by AI

Does this investigation offer participation for elderly individuals?

"The requirements for enrolment into this trial restrict participants to those aged between 4 and 18. Specifically, 90 studies are looking at patients younger than 18 while 223 target those over 65 years old."

Answered by AI

How many individuals is the capacity for this clinical trial?

"Affirmative. According to information stored on clinicaltrials.gov, this medical trial is in active recruitment for 420 participants across 1 site. This study was originally posted on August 19th 2021 and most recently updated on February 11th 2022."

Answered by AI